SCHEMBL23997201

SCHEMBL23997201

O=c1[nH]c2ccccc2n1C(F)F

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.68
DAO P14920 1/20 0.58
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
KMT2A Q03164 1/20 0.49
IDO1 P14902 1/20 0.47
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HSP90AA1 P07900 5/20 0.44
LMNA P02545 2/20 0.42
HTT P42858 2/20 0.42
AURKA O14965 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PGR P06401 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30336952 1.00 POLB (0.68) POLBDAOMEN1CYP1A2KMT2A
SCHEMBL828232 0.81 POLB (1.00) POLBDAOMEN1CYP1A2KMT2A
SCHEMBL30838374 0.81 POLB (1.00) POLBDAOMEN1CYP1A2KMT2A
SCHEMBL7017890 0.78 POLB (0.74) POLBDAOMEN1CYP1A2KMT2A
SCHEMBL904825 0.78 POLB (0.74) POLBDAOMEN1CYP1A2KMT2A
SCHEMBL10736441 0.78 POLB (0.74) POLBDAOMEN1CYP1A2KMT2A
SCHEMBL7513143 0.78 POLB (0.68) POLBDAOMEN1CYP1A2KMT2A
SCHEMBL11768003 0.78 POLB (0.58) POLBDAOMEN1CYP1A2KMT2A
SCHEMBL27143489 0.78 POLB (0.58) POLBDAOMEN1CYP1A2KMT2A
SCHEMBL14622076 0.77 POLB (0.67) POLBDAOMEN1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454525-B2 IL4I1 inhibitors and methods of use MERCK SHARP & DOHME LLC (US) 2025-10-28 US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
CN-115836054-A IL4I1 inhibitors and methods of use 默沙东有限责任公司 2023-03-21 CN disclosed
WO-2021226003-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 POLB 4386/4885DAO 3751/4885MEN1 1034/4885
US-12454525-B2 IL4I1 inhibitors and methods of use IL4I1, IL4, IL2 POLB 4386/4885DAO 3751/4885MEN1 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.